<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536848</url>
  </required_header>
  <id_info>
    <org_study_id>MRRC HIV-Probiotics15</org_study_id>
    <nct_id>NCT00536848</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients</brief_title>
  <official_title>The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sekou-Toure Regional Hosipital, Mwanza, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danone Institute International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute for Medical Research, Tanzania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to asses whether probiotics Lactobacillus rhamnosus (GR-1) and
      reuteri (RC-14) are able to prevent diarrhea, delay the decline of the immune system and
      prevent and/or cure bacterial vaginosis among HIV patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Two third of all people infected with HIV live in Sub-Saharan Africa. A region
      also affected with a great burden of other infectious diseases. Relatively few patients have
      access to anti-retroviral treatment and many suffer from debilitating diarrhea that causes
      their immune system to deteriorate. Prevention of infectious diseases among HIV patients is
      of great importance and makes the immune system deteriorate less rapidly. The track record
      for probiotics to prevent and alleviate infectious diarrhea is impressive. So, the use of
      probiotics among HIV patients is a logical step and could be an adjunctive tool for
      physicians to halt the decline of the CD4 count.

      Another important application for the use of probiotics is in the treatment of bacterial
      vaginosis (BV). BV is a vaginal infection, caused by a group of pathogens, which is extremely
      common, and estimated to occur in 50% of black African women. In the US, the prevalence is
      29%, which again is extremely high. This infection makes a woman more vulnerable to
      contracting sexually transmitted infections, including HIV. Having BV is also a risk factor
      to transmit HIV to a partner or a newborn. Conventional antibiotic treatment of BV has a cure
      rate of 40% among black African women. A recent study shows that combining the probiotic
      strains Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 with an antibiotic has a
      cure rate of 88%.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">August 2008</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD4 count</measure>
    <time_frame>assessed at 10 and 25 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bacterial vaginosis cure rate</measure>
    <time_frame>assesed at week 2, 5, 15, 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total serum IgE levels</measure>
    <time_frame>baseline and at 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cytokine levels</measure>
    <time_frame>baseline and at 10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea incidence and length of episodes</measure>
    <time_frame>25 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>HIV Infections</condition>
  <condition>Diarrhea</condition>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronidazole for 10 days, probiotics for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metronidazole for 10 days, placebo for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed HIV infection.

          -  Participant does not meet the criteria for ARV therapy, CD4 count &gt; 200, no clinical
             stage 3 or 4 [National guidelines, 2005].

          -  Having an intermediate Nugent score (4-6), or a positive Nugent score (7-10).

        Exclusion Criteria:

          -  Pregnancy or lactating.

          -  Menstruation at time of diagnosis.

          -  Hypersensitive to metronidazole/warfarin/lithium/disulfiram.

          -  Not willing to avoid alcohol use during the metronidazole treatment of 10 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Changalucha, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Medical Research, Mwanza Research Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sekou-Toure Regional Hospital</name>
      <address>
        <city>Mwanza</city>
        <zip>p.o. box 1663</zip>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <link>
    <url>http://www.westernheadseast.ca</url>
    <description>a project of the University of Western Ontario to bring probiotics to the developing world</description>
  </link>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director</name_title>
    <organization>National Institute for Medical Research, Mwanza research centre</organization>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Diarrhea</keyword>
  <keyword>Lactobacillus rhamnosus GR-1</keyword>
  <keyword>Lactobacillus reuteri RC-14</keyword>
  <keyword>Immune system</keyword>
  <keyword>Infectious Diseases</keyword>
  <keyword>Complementary Therapies</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

